Koh Yasuhiro, Matsumi Shintaro, Das Debananda, Amano Masayuki, Davis David A, Li Jianfeng, Leschenko Sofiya, Baldridge Abigail, Shioda Tatsuo, Yarchoan Robert, Ghosh Arun K, Mitsuya Hiroaki
Department of Hematology, Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, 1-1-1 Honjo, Kumamoto 860-8556, Japan; Department of Infectious Diseases, Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, 1-1-1 Honjo, Kumamoto 860-8556, Japan.
Experimental Retrovirology Section, NCI, National Institutes of Health, Bethesda, Maryland 20892.
J Biol Chem. 2007 Sep 28;282(39):28709-28720. doi: 10.1074/jbc.M703938200. Epub 2007 Jul 17.
Dimerization of HIV-1 protease subunits is essential for its proteolytic activity, which plays a critical role in HIV-1 replication. Hence, the inhibition of protease dimerization represents a unique target for potential intervention of HIV-1. We developed an intermolecular fluorescence resonance energy transfer-based HIV-1-expression assay employing cyan and yellow fluorescent protein-tagged protease monomers. Using this assay, we identified non-peptidyl small molecule inhibitors of protease dimerization. These inhibitors, including darunavir and two experimental protease inhibitors, blocked protease dimerization at concentrations of as low as 0.01 microm and blocked HIV-1 replication with IC(50) values of 0.0002-0.48 microm. These agents also inhibited the proteolytic activity of mature protease. Other approved anti-HIV-1 agents examined except tipranavir, a CCR5 inhibitor, and soluble CD4 failed to block the dimerization event. Once protease monomers dimerize to become mature protease, mature protease is not dissociated by this dimerization inhibition mechanism, suggesting that these agents block dimerization at the nascent stage of protease maturation. The proteolytic activity of mature protease that managed to undergo dimerization despite the presence of these agents is likely to be inhibited by the same agents acting as conventional protease inhibitors. Such a dual inhibition mechanism should lead to highly potent inhibition of HIV-1.
HIV-1蛋白酶亚基的二聚化对其蛋白水解活性至关重要,而该活性在HIV-1复制中起着关键作用。因此,抑制蛋白酶二聚化是HIV-1潜在干预的一个独特靶点。我们开发了一种基于分子间荧光共振能量转移的HIV-1表达检测方法,该方法采用了青色和黄色荧光蛋白标记的蛋白酶单体。利用该检测方法,我们鉴定出了蛋白酶二聚化的非肽基小分子抑制剂。这些抑制剂,包括地瑞那韦和两种实验性蛋白酶抑制剂,在低至0.01微摩尔的浓度下就能阻断蛋白酶二聚化,并以0.0002 - 0.48微摩尔的半数抑制浓度(IC50)阻断HIV-1复制。这些药物还抑制了成熟蛋白酶的蛋白水解活性。除了CCR5抑制剂替拉那韦和可溶性CD4外,所检测的其他已批准的抗HIV-1药物均未能阻断二聚化过程。一旦蛋白酶单体二聚化成为成熟蛋白酶,成熟蛋白酶不会因这种二聚化抑制机制而解离,这表明这些药物在蛋白酶成熟的新生阶段阻断二聚化。尽管存在这些药物,仍成功发生二聚化的成熟蛋白酶的蛋白水解活性可能会被这些作为传统蛋白酶抑制剂的药物所抑制。这种双重抑制机制应该会导致对HIV-1的高效抑制。